PureFDA Medical Technology (Guangzhou) Co., LTD., a Hong Kong-based SaaS + Data service life science service provider, completed an over CNY100M Series B financing.
The round was led by Legend Capital followed by the existing shareholder Bayland Capital.
The funds will mainly be used for the construction of overseas medical device resources, the expansion of the professional talent team, the strategic expansion of the medical devices field, and the upgrading and iteration of the big data information platform.
Founded in June 2020 by MENG Zhu, PureFDA is a SaaS + Data service life science service provider that focuses on whole-process informatization of medical devices going overseas in the global market. Besides, the company is dedicated to providing whole-process consulting services for compliance access to the global market for products such as medical devices, in vitro diagnostics and medical software AI, covering device regulations consultation, local authorized representatives, product certification and registration, overseas clinical trials, technical documentation and system guidance, product testing, etc.
The company’s service network has spread to 10 countries and regions worldwide, including the United States, Germany, Italy, Spain, Switzerland and Poland. PureFDA has 8 branch companies and possesses scarce clinical resources in the industry. Its overseas clinical centers in Europe and the United States have been certified with qualifications such as CLIA, CAP and ISO 17025.
FinSMEs
10/11/2022